title: Synthesis and biological activity of new HMG-CoA reductase inhibitors. 3. Lactones of 6-phenoxy-3,5-dihydroxyhexanoic acids.
abstract: A group of 43 optically active sodium carboxylates (11a-qq and the corresponding lactones 4 were prepared from respective phenols 8 according to Schemes I-III. Phenols 8 were synthesized from commercially available compounds according to Schemes IV-IX. A number of these HMG-CoA reductase inhibitors 11 exceeded mevinolin's activity in vitro (Tables II and III). Selected lactones 4 effectively inhibited hepatic "de novo" cholesterol synthesis in rats in vivo (Table IV). After po administration to rabbits, 4ff(11ff), 4hh, and notably 11jj reduced plasma cholesterol levels more potently than mevinolin (Table V). Whereas 4ff(11ff) displayed the slight superiority expected according to in vitro data, 4hh and 11jj were considerably more potent than expected. Each of these compounds had only moderate activity after po administration to dogs (Table VI). Compound di-11ii, a hybrid of the structural elements of probucol and HMG-CoA reductase inhibitors, after po administration to rats decreased serum lipoproteins and increased HDL/LDL ratio better than probucol (Table VII). HMG-CoA reductase inhibitor 11ll and phenolic building blocks 8, notably 8jj and 8kk, inhibited LDL oxidation in vitro (Table VIII). Chemical structure-activity relationships (Table IX) and the pharmacological profile of phenoxy-type inhibitors 11 diverged from those of known HMG-CoA reductase inhibitors.
authors.affiliation: Hoechst AG, Frankfurt, Germany.
authors.forename: H
authors.initials: H
authors.lastname: Jendralla
authors.forename: E
authors.initials: E
authors.lastname: Granzer
authors.forename: B
authors.initials: B
authors.lastname: von Kerekjarto
authors.forename: R
authors.initials: R
authors.lastname: Krause
authors.forename: U
authors.initials: U
authors.lastname: Schacht
authors.forename: E
authors.initials: E
authors.lastname: Baader
authors.forename: W
authors.initials: W
authors.lastname: Bartmann
authors.forename: G
authors.initials: G
authors.lastname: Beck
authors.forename: A
authors.initials: A
authors.lastname: Bergmann
authors.forename: K
authors.initials: K
authors.lastname: Kesseler
mesh_terms: D000818:Animals; D000924:Anticholesteremic Agents / Q000138:chemical synthesis / Q000494:pharmacology*; D002208:Caproates / Q000138:chemical synthesis / Q000494:pharmacology*; D006528:Carcinoma, Hepatocellular / Q000201:enzymology; D002784:Cholesterol / Q000096:biosynthesis / Q000097:blood; D004285:Dogs; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007783:Lactones / Q000138:chemical synthesis / Q000494:pharmacology*; D008099:Liver / Q000201:enzymology; D008113:Liver Neoplasms / Q000201:enzymology; D008148:Lovastatin / Q000494:pharmacology; D008297:Male; D015394:Molecular Structure; D011817:Rabbits; D051381:Rats; D013329:Structure-Activity Relationship; D014407:Tumor Cells, Cultured
chemical_list: D000924:Anticholesteremic Agents; D002208:Caproates; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007783:Lactones; D002784:Cholesterol; D008148:Lovastatin